Nifty October futures trade at premium

Nifty October futures trade at premium


Tata Consultancy Services, Infosys and Reliance Industries were the top traded contracts.

The Nifty October 2024 futures closed at 25,048, a premium of 83.75 points compared with the Nifty’s closing 24,964.25 in the cash market.

In the cash market, the Nifty 50 lost 34.20 points or 0.14% to 24,964.25.

Click here to connect with us on WhatsApp

The NSE’s India VIX, a gauge of market’s expectation of volatility over the near term, shed 1.24% to 13.33.

Tata Consultancy Services, Infosys and Reliance Industries were the top traded individual stock futures contracts in F&O segment of NSE.

The October 2024 F&O contracts will expire on 31 October 2024.

 

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Oct 11 2024 | 4:20 PM IST



Source link

IPO aimed at further localising India operations: Hyundai Motor India COO

IPO aimed at further localising India operations: Hyundai Motor India COO


Tarun Garg, chief operating officer of Hyundai Motor India (HMIL)


The upcoming Rs 27,870 crore initial public offering of the Indian arm of South Korean automaker Hyundai, the first such instance of the company listing its subsidiary in an overseas market, is aimed to further Indianise operations, a senior company official said on Friday.


Hyundai Motor India Ltd’s initial public offering (IPO), the largest in the country’s history, will open for public subscription on October 15 and conclude on October 17. Anchor investors will bid on October 14.

Click here to connect with us on WhatsApp


“We have been in India now for more than 26 years. We have a very high market share. We are at number two position in India in the passenger vehicle space. We have got so much love and affection from the people of India. So we believe this is the right time to take one step forward and even further Indianise our operations,” Hyundai Motor India Ltd (HMIL) COO Tarun Garg told PTI.

 


He further said,” The whole aim is to really become the most trusted brand of India.”

Garg was responding to a query behind reasons for the company choosing India for a public listing and not other countries.


“If you see India as a country, it is really doing very well. The GDP is very good, much higher than the global GDP growth rates,” he said, adding in the last three to four years, India has emerged as a very good destination for all the major players and the pace of growth even further accelerated.


Also, with the company’s growth story set to further accelerate in India, Garg said it is an opportune time to go public.


“The Pune plant (acquired from General Motors) is also coming (up). We believe that this is the right time to invite and give the opportunity to all the local investors, as well as the global investors, to become a part of this growth story…this is something very important, and it will really make us more inclusive,” Garg noted.


Moreover, he said,”This IPO gives us an opportunity to really pursue some global standards in terms of excellence, in terms of operations, in terms of governance. All these things are really working in favour of an IPO.”

On Hyundai choosing the Indian arm for a public listing and not other countries’, Garg said,”We are number two player in India (in passenger vehicles), outside of (South) Korea…and we have a double-digit market share. These two are very significant points and that Hyundai in India has done really well, that gives the confidence.”

Further, he said,”The brand Hyundai has really been accepted very well in India. We have been able to appeal to the Indian people generally. This is probably the right country to really go for the IPO.”

HMIL has set a price band of Rs 1,865 to Rs 1,960 per share for the offering, valuing the automaker at Rs 1.6 lakh crore (about USD 19 billion). At the upper end of the price band, the IPO size has been pegged at Rs 27,870 crore.


The company’s IPO will surpass the Rs 21,000 crore offering by Life Insurance Corporation of India (LIC) in May 2022.

First Published: Oct 11 2024 | 4:17 PM IST



Source link

Nifty October futures trade at premium

CRISIL Ratings revises TVS Holdings' outlook to 'positive'; reaffirms 'AA' rating


TVS Holdings (TVSHL) said that CRISIL Ratings has revised its outlook on the long-term bank facility and non-convertible debentures (NCDs) of the company to ‘positive’ from ‘stable’ while reaffirming the rating at ‘CRISIL AA’.

CRISIL Ratings stated that the outlook revision factors the healthy improvement in credit profile of its main operating company, TVS Motor Company (TVSM).

Click here to connect with us on WhatsApp

The improvement is driven by healthy gain in market share for TVSM over the past 3-4 fiscals in motorcycle and scooter segments backed by expansion of product portfolio including launch of electric scooters and market reach through dealership expansion.

 

The growth momentum of TVSM will continue over the medium term as well supported by healthy market position in motorcycle and scooter segment.

Operating profitability at consolidated level is constrained on account of losses in the overseas subsidiaries due to product development costs and muted demand scenario in Europe. The losses are expected to gradually decline over the medium term with launch of new products and ramp up of utilization levels. which will aid TVSMs overall operating profitability.

Besides, TVSMs financial risk profile also continues to improve over time, driven by healthy cash generation and prudent capital spend.

In addition, TVSHL holds 50.26% stake in TVSM which is valued at Rs 68,718 crore as on 27 September 2024 which translates to healthy debt cover of over 100x (debt of Rs 650 crore as on date). The healthy debt cover provides adequate financial flexibility for TVSHL.

“Owing to healthy relationships with lending community and comfortable debt cover because of the holding in TVSM, refinancing will not be a challenge. However, material decline in debt cover, including debt raised for sizeable additional acquisition or investments in subsidiaries, or fall in share price of TVSM will remain monitorables,” the rating agency said.

TVS Holdings (TVSHL) [formerly Sundaram Clayton (SCL)] was a leading manufacturer of aluminium die-casting components. Until fiscal 2007, SCLs financials included the CV brakes business. With effect from March 28, 2008, the Madras High Court approved the de-merger of the brakes business into a separate company, Wabco India Ltd. The non-brakes business (aluminium die-casting) and investments in the TVS group entities remained with SCL. During fiscal 2012, SCL restructured its businesses, hiving off the non-automotive businesses into its erstwhile subsidiary, Sundaram Investments Ltd (SIL).

In August 2023, the aluminium diecasting business of SCL was demerged into a separate entity, SCL DCD and SCL was renamed as TVSHL which retained the investments in TVS Motor Company (TVSM) and real estate entity TVS Emerald (TEL).

The scrip lost 0.41% to end at Rs 13290.30 on the BSE today.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Oct 11 2024 | 4:15 PM IST



Source link

Nifty October futures trade at premium

Anand Rathi Q2 PAT climbs 32% YoY to Rs 76 cr in FY25


The financial products distributor’s consolidated net profit jumped 32.38% to Rs 76.11 crore in Q2 FY25 as compared to Rs 57.49 crore posted in Q2 FY24.

Revenue from operations surged 32.80% YoY to Rs 242.48 crore in the quarter ended 30 September 2024.

For the quarter ended 30 September 2024, profit before tax was Rs 102.18 crore, reflecting a growth of 31.47% compared to Rs 77.72 crore posted in the same quarter previous year.

Click here to connect with us on WhatsApp

During the quarter, assets under management (AUM) stood at Rs 75,084 crore, up 57% as compared with Rs 47,957 crore recorded in Q2 FY24. Share of Equity Mutual Funds in AUM increased to 55% as of September 2024 and 50% as of September 2023.

 

In Q2 FY25, the companys net inflows surged by 128% year-on-year to Rs 5,700 crore, while net inflows in Equity Mutual Funds increased by 64% YoY to Rs 3,116 crore for the quarter ended 30 September 2024.

Mutual Fund distribution revenue rose by 70% YoY to Rs 195 crore, while the annualized Return on Equity (ROE) stood at 44%.

On half-year basis, the company’s consolidated net profit jumped 35.09% to Rs 149.35 crore in H1 FY25 as against 110.55 crore posted in H1 FY24. The compays Revenue surged 34.25% YoY to Rs 480.09 crore in H1 FY25.

Meanwhile, the companys board declared interim dividend of Rs 7 per share of face value of Rs 5 each for FY25. The company has fixed 18 October 2024 as record date for the said dividend.

Rakesh Rawal, chief executive officer (CEO), said, We are thrilled to announce another exceptional financial result. In H1 FY25 our total revenue grew by 35% year-on-year to Rs 495 crore and Profit after Tax was Rs 150 crore, representing growth of 35% year-on-year. Our Assets Under Management (AUM) has seen a significant increase of 57% to Rs 75,084 crore. In the first half of FY25, we welcomed 1,066 new client families, bringing our total count of client families to 10,977.

Indias growth story is being celebrated as the global economy faces geopolitical challenges and slow growth. As the fastest-growing large economy, India is projected to achieve a 7% GDP growth for FY25, driven by strong domestic demand, government reforms and increased capital expenditure, which has also boosted its market capitalization.

In light of such strong economic growth, the companys prospects are positive, supported by the rising HNI population who are seeking a strategic approach to wealth creation.

Feroze Azeez, deputy chief executive Officer said, Indias strong economic fundamentals have driven increased interest from both domestic and foreign investors. This trend is reflected in consistent inflows into the equity markets, with new investments hitting record highs month-on-month. Such a positive momentum is expected to strengthen the Indian equity markets further, fostering an environment conducive to long-term capital appreciation and broadening of the investor base.

Our client centric approach has resulted in 0.28% client attrition rate in terms of AUM lost during the first half of FY25. We take immense pride in achieving zero regret RM attrition for the fifth consecutive quartera true testament to our robust entrepreneurial work culture and unwavering commitment to our teams growth and satisfaction.

Anand Rathi Wealth is among Indias leading non-bank wealth solutions firms, catering to high and ultra-high net worth individuals.

The scrip shed 0.37% to settled at Rs 4,040.50 on the BSE.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Oct 11 2024 | 4:08 PM IST



Source link

Nifty October futures trade at premium

Quick Wrap: Nifty Pharma Index gains 1.19%


Nifty Pharma index ended up 1.19% at 23582.25 today. The index has gained 2.00% over last one month. Among the constituents, Granules India Ltd rose 4.40%, Ipca Laboratories Ltd added 4.09% and Mankind Pharma Ltd gained 4.04%. The Nifty Pharma index has soared 55.00% over last one year compared to the 26.12% increase in benchmark Nifty 50 index. In other indices, Nifty Metal index gained 0.94% and Nifty Bank index has dropped 0.70% on the day. In broad markets, the Nifty 50 has dropped 0.14% to close at 24964.25 while the SENSEX has slid 0.28% to close at 81381.36 today.

Powered by Capital Market – Live News

 

Click here to connect with us on WhatsApp

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Oct 11 2024 | 4:00 PM IST



Source link

Mukul Agrawal portfolio stock zooms 122% in 4 months; up 1100% in 25 months

Mukul Agrawal portfolio stock zooms 122% in 4 months; up 1100% in 25 months



Neuland Laboratories share price hit a new high of Rs 14,500 on the BSE on Friday, surging 16 per cent in the intraday. The shares, however, closed 12.8 per cent higher at Rs 14,100 on the BSE on expectation of a strong September quarter earnings (Q2FY25). In comparison, the BSE Sensex ended 0.28 per cent lower at 81,381.


In the last four months, Neuland Labs share price has more-than-doubled, zooming 122 per cent, as the company posted robust earnings for the June 2024 quarter (Q1FY25). Since September 9, 2022, in the last 25 months, it has skyrocketed 1,100 per cent or 12 times from a level of Rs 1,201 on the BSE.

Click here to connect with us on WhatsApp

 


Investor Mukul Mahavir Agrawal held 400,000 shares, representing 3.12 per cent stake, in Neuland Lab at the end of June quarter, shareholding pattern data shows.


The company has not yet disclosed the shareholding pattern for the quarter ended September 2024.


Neuland Labs is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions (CMS) services to customers.


The company recorded its highest-ever quarterly revenue in Q1FY25 at Rs 444.4 crore led by growth in the CMS business. The company recorded healthy earnings before interest, taxes, depreciation, and amortisation (Ebitda) margins at 28.9 per cent, up 174 bps over Q1FY24. Profit after tax jumped 58 per cent year-on-year at Rs 98.3 crore from Rs 62.2 crore in the year-ago quarter.


The management said the company continues to maintain that FY25 will be a year of normalisation of revenue growth and subsequently margins as the company continue to invest for growth. The management expect the company’s business to regain momentum from FY26 onwards, basis its visibility from the company’s portfolio of projects and products.


“As we evaluate our pipeline of projects and the flow of new projects, we remain enthusiastic on the strong potential of the CMS business over the long term. The Generic Drug Substances (GDS) business continues to build on the strong base we have with quality focussed customers, even as our R&D team is working on an exciting set of molecules to add to our portfolio,” the management had said while announcing its Q1FY25 results on August 1.


Meanwhile, the market for API within the CDMO sector is likely valued at $118.09 billion in 2024 and is expected to grow to $178.47 billion by 2029. This growth represents a compound annual growth rate (CAGR) of 8.61 per cent from 2024 to 2029.


“There has been a noticeable trend towards increased outsourcing to CDMOs in the pharmaceutical industry. This shift allows companies to leverage the expertise, flexibility, and specialised skills offered by CDMOs. Organisations of all sizes, from small drug developers to large pharmaceutical and bio pharmaceutical companies spanning both early and late-stage development projects, are adopting this outsourcing strategy,” Neuland Lab said in its FY24 annual report.


The revenue contribution from niche API and CMS will continue to increase over the next three years while that of prime API segment is expected to remain around 25 per cent. Healthy relationships with top pharma players and strong R&D capabilities ensure healthy operating margin, according to CRISIL Ratings.


The group caters to clients in India and overseas. It derives over 80 per cent of its revenue from export. In the CMS business, the entire revenue comes from regulated markets, such as the US, Europe and Japan. Diversity in geographic reach and clientele will continue to support the business risk profile, the ratings agency had said in its rationale dated March 27, 2024.

First Published: Oct 11 2024 | 3:53 PM IST



Source link

YouTube
Instagram
WhatsApp